207 related articles for article (PubMed ID: 24232122)
1. Vincristine sulfate liposomal injection for acute lymphoblastic leukemia.
Raj TA; Smith AM; Moore AS
Int J Nanomedicine; 2013; 8():4361-9. PubMed ID: 24232122
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of vincristine sulfate liposome injection (VSLI) in adults with acute lymphoblastic leukemia.
Silverman JA; Reynolds L; Deitcher SR
J Clin Pharmacol; 2013 Nov; 53(11):1139-45. PubMed ID: 23907766
[TBL] [Abstract][Full Text] [Related]
3. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.
O'Brien S; Schiller G; Lister J; Damon L; Goldberg S; Aulitzky W; Ben-Yehuda D; Stock W; Coutre S; Douer D; Heffner LT; Larson M; Seiter K; Smith S; Assouline S; Kuriakose P; Maness L; Nagler A; Rowe J; Schaich M; Shpilberg O; Yee K; Schmieder G; Silverman JA; Thomas D; Deitcher SR; Kantarjian H
J Clin Oncol; 2013 Feb; 31(6):676-83. PubMed ID: 23169518
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Vincristine Sulfate Liposome Injection in the Treatment of Adult Acute Lymphocytic Leukemia.
Douer D
Oncologist; 2016 Jul; 21(7):840-7. PubMed ID: 27328933
[TBL] [Abstract][Full Text] [Related]
5. High-Dose Vincristine Sulfate Liposome Injection, for Advanced, Relapsed, or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in an Adolescent and Young Adult Subgroup of a Phase 2 Clinical Trial.
Schiller GJ; Damon LE; Coutre SE; Hsu P; Bhat G; Douer D
J Adolesc Young Adult Oncol; 2018 Oct; 7(5):546-552. PubMed ID: 30239252
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia.
Thomas DA; Kantarjian HM; Stock W; Heffner LT; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Pierce S; Lu B; Deitcher SR; O'Brien S
Cancer; 2009 Dec; 115(23):5490-8. PubMed ID: 19708032
[TBL] [Abstract][Full Text] [Related]
7. Vincristine-Loaded and sgc8-Modified Liposome as a Potential Targeted Drug Delivery System for Treating Acute Lymphoblastic Leukemia.
Duan S; Yu Y; Lai C; Wang D; Wang Y; Xue D; Hu Z; Lu X
J Biomed Nanotechnol; 2018 May; 14(5):910-921. PubMed ID: 29883561
[TBL] [Abstract][Full Text] [Related]
8. Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®): Results From a Phase I Study in Children, Adolescents, and Young Adults With Refractory Solid Tumors or Leukemias.
Shah NN; Merchant MS; Cole DE; Jayaprakash N; Bernstein D; Delbrook C; Richards K; Widemann BC; Wayne AS
Pediatr Blood Cancer; 2016 Jun; 63(6):997-1005. PubMed ID: 26891067
[TBL] [Abstract][Full Text] [Related]
9. Vincristine Sulfate Liposome Injection with Bendamustine and Rituximab as First-Line Therapy for B-Cell Lymphomas: A Phase I Study.
Ollila T; Butera J; Egan P; Reagan J; Thomas A; Yakirevich I; MacKinnon K; Margolis J; McMahon J; Rosati V; Olszewski AJ
Oncologist; 2022 Jul; 27(7):532-e542. PubMed ID: 35641232
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic characteristics of vincristine sulfate liposomes in patients with advanced solid tumors.
Yan Z; Zhu ZL; Qian ZZ; Hu G; Wang HQ; Liu WH; Cheng G
Acta Pharmacol Sin; 2012 Jun; 33(6):852-8. PubMed ID: 22669119
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma.
Yang F; Jiang M; Lu M; Hu P; Wang H; Jiang J
Front Pharmacol; 2018; 9():991. PubMed ID: 30210349
[No Abstract] [Full Text] [Related]
12. Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine.
Davis T; Farag SS
Int J Nanomedicine; 2013; 8():3479-88. PubMed ID: 24072970
[TBL] [Abstract][Full Text] [Related]
13. Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine.
Silverman JA; Deitcher SR
Cancer Chemother Pharmacol; 2013 Mar; 71(3):555-64. PubMed ID: 23212117
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia.
Thomas DA; Sarris AH; Cortes J; Faderl S; O'Brien S; Giles FJ; Garcia-Manero G; Rodriguez MA; Cabanillas F; Kantarjian H
Cancer; 2006 Jan; 106(1):120-7. PubMed ID: 16331634
[TBL] [Abstract][Full Text] [Related]
15. Identification of small molecules that mitigate vincristine-induced neurotoxicity while sensitizing leukemia cells to vincristine.
Diouf B; Wing C; Panetta JC; Eddins D; Lin W; Yang W; Fan Y; Pei D; Cheng C; Delaney SM; Zhang W; Bonten EJ; Crews KR; Paugh SW; Li L; Freeman BB; Autry RJ; Beard JA; Ferguson DC; Janke LJ; Ness KK; Chen T; Zakharenko SS; Jeha S; Pui CH; Relling MV; Eileen Dolan M; Evans WE
Clin Transl Sci; 2021 Jul; 14(4):1490-1504. PubMed ID: 33742760
[TBL] [Abstract][Full Text] [Related]
16. Liposomal vincristine for relapsed or refractory Ph-negative acute lymphoblastic leukemia: a review of literature.
Pathak P; Hess R; Weiss MA
Ther Adv Hematol; 2014 Feb; 5(1):18-24. PubMed ID: 24490021
[TBL] [Abstract][Full Text] [Related]
17. Plasma and cerebrospinal fluid pharmacokinetics of vincristine and vincristine sulfate liposomes injection (VSLI, marqibo®) after intravenous administration in Non-human primates.
Shah NN; Cole DE; Lester-McCully CM; Wayne AS; Warren KE; Widemann BC
Invest New Drugs; 2016 Feb; 34(1):61-5. PubMed ID: 26661090
[TBL] [Abstract][Full Text] [Related]
18. Incidence of vincristine induced neurotoxicity in children with acute lymphoblastic leukemia and its correlation with nutritional deficiencies.
Dudeja S; Gupta S; Sharma S; Jain A; Sharma S; Jain P; Aneja S; Chandra J
Pediatr Hematol Oncol; 2019 Sep; 36(6):344-351. PubMed ID: 31514565
[TBL] [Abstract][Full Text] [Related]
19. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas.
Hagemeister F; Rodriguez MA; Deitcher SR; Younes A; Fayad L; Goy A; Dang NH; Forman A; McLaughlin P; Medeiros LJ; Pro B; Romaguera J; Samaniego F; Silverman JA; Sarris A; Cabanillas F
Br J Haematol; 2013 Sep; 162(5):631-8. PubMed ID: 23802738
[TBL] [Abstract][Full Text] [Related]
20. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial.
Sarris AH; Hagemeister F; Romaguera J; Rodriguez MA; McLaughlin P; Tsimberidou AM; Medeiros LJ; Samuels B; Pate O; Oholendt M; Kantarjian H; Burge C; Cabanillas F
Ann Oncol; 2000 Jan; 11(1):69-72. PubMed ID: 10690390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
